• 22 December 2020: OIA response: funding for blood glucose monitors via Named Patient Pharmaceutical Assessment

• 21 December 2020: OIA response: average age of initiation of statin therapy in New Zealand

• 21 December 2020: OIA response: cannabidiol with tetrahydrocannabinol (Sativex) clinical advice paper for PTAC

• 11 December 2020: OIA response: Special authority data for temozolomide for the treatment of neuroendocrine tumours

• 4 December 2020: OIA response: organisations who responded to proposal to fund two new medicines for type 2 diabetes

• 3 December 2020: OIA response: funding data for rare disorders medicines

• 3 December 2020: OIA response: FreeStyle Libre flash glucose monitor and Dexcom continuous glucose monitor, Tandem insulin pump

• 2 December 2020: OIA response: anti-vascular endothelial growth factor (“anti-VEGF”) agents

• 27 November 2020: OIA response: special authority approvals for adalimumab, etanercept, secukinumab,

• 25 November 2020: OIA response: Special authority funding data for insulin pump consumables

• 24 November 2020: OIA response: funding for blood glucose monitors and test strips

• 19 November 2020: OIA response: decision to change the tetanus vaccine and immunisation schedule

• 18 November 2020: OIA response: cost of funding oral vinorelbine

• 18 November 2020: OIA response: information relating to funding continuous glucose monitors (CGMs)

• 16 November 2020: OIA response: public funding of Trikafta

• 16 November 2020: OIA response: consultation submissions for proposal to modify PHARMAC’s approach t

• 16 November 2020: OIA response: fingolimod use and annual expenditure (2017-2020)

• 05 November 2020: OIA response: ustekinumab NPPA applications for Crohn’s disease and/or ulcerative

• 2 November 2020: OIA response: Hydroxychloroquine in the treatment of COVID-19

• 28 October 2020: OIA response: Special Authority approval data for olaparib, rituximab

• 20 October 2020: OIA response: Special Authority data for somatropin and pegylated interferon alfa-2

• 16 October 2020: OIA response: Canterbury DHB distribution/dispensing data for influenza vaccine, an

• 15 October 2020: OIA response: Information related to PHARMAC employee remuneration/salary bands

• 14 October 2020: OIA response: Dispensing data for siltuximab, tocilizumab and bedaquiline

• 12 October 2020: OIA response: Decision process for funding criteria for teriparatide (Forteo)

• 11 October 2019: OIA response: Cancer drugs data

• 2 October 2020: OIA response: Multiple scerosis (MS) patient numbers

• 1 October 2020: OIA response: Funding data for ustekinumab via the Exceptional Circumstances Framewo

• 1 October 2020: OIA response: Special Authority funding data for lenalidomide (Revlimid)

• 20 November 2020: OIA response: implications of switching from pharmaceuticals to medicinal cannabis

• 30 September 2020: OIA response: Funding data for Hylo-Fresh eye drops

• 29 September 2020: OIA response: Information regarding Named Patient Pharmaceutical Assessment (NPPA

• 28 September 2020: OIA response: Application data for multiple sclerosis treatments

• 24 September 2020: OIA response: Cost-benefit analysis for ustekinumab

• 24 September 2020: OIA response: Patient numbers and cost utility analysis for ivacaftor (Kalydeco)

• 18 September 2020: OIA response: Funding plans for progesterone only oral contraceptive pill (POP) d

• 3 September 2020: OIA response: Erectile dysfunction medications available and funded in New Zealand

• 3 September 2020: OIA response: Cost of funding tramadol in 2019

• 28 August 2020: OIA response: Droperidol supply data

• 28 August 2020: OIA response: Data for funded intravenous iron usage

• 28 August 2020: OIA response: Data for HIV antiretroviral usage

• 17 August 2020: OIA response: Information regarding subsidised prescriptions for goserelin and leupr

• 13 August 2020: OIA response: Special Authority data for pembrolizumab and nivolumab for June 2020

• 10 August 2020: OIA response: Information regarding PTAC subcommittee minutes

• 5 August 2020: OIA Response: Information regarding Spinraza funding

• 30 July 2020: OIA response: Dispensing NPPA B medicines

• 29 July 2020: OIA response: Information related to the prescription and/or use of generic medicines

• 28 July 2020: OIA response: annual funding volumes of trastuzumab

• 28 July 2020: OIA response: indemnities sought from pharmaceutical companies for out-of-stock/supply issues

• 27 July 2020: OIA response: funding and purchase data for lenalidomide and bortezomib 

• 20 July 2020: OIA response: medicines funded for the treatment of multiple sclerosis

• 20 July 2020: OIA response: annual funding of food thickeners Aptamil and Nutilis

• 20 July 2020: OIA response: hospital purchasing data and Special Authority approvals for azacitidine

• 16 July 2020: OIA response: Special Authority approvals for methylphenidate for treatment of ADHD vs narcolepsy

• 16 July 2020: OIA response: Hydroxychloroquine for the treatment or prevention of COVID-19

• 16 July 2020: OIA response: Anaesthetic gases

• 16 July 2020: OIA response: Special Authority data for Risperdal Consta, Zyprexa Relprevv, Invega Sustenna

• 15 July 2020: OIA response: payments to the New Zealand Drug Foundation

• 13 July 2020: OIA response: Special Authority and funding data for anti-epileptic medicines

• 9 July 2020: OIA response: Special Authority approval data for enoxaparin sodium

• 3 July 2020: OIA response: Special Authority data for ADHD medicines

• 3 July 2020: OIA response: Ministerial briefings – medicines supply and funding decisions

• 3 July 2020: OIA response: ministerial briefings

• 25 June 2020: OIA response: NPPA applications and exceptional circumstances applications for lamotri

• 19 June 2020: OIA response: Discontinuation of phenelzine sulphate

• 19 June 2020: OIA response: Pembrolizumab and nivolumab

• 19 June 2020: OIA response: Ritalin

• 18 June 2020: OIA response: Nationwide Special Authority data by immunology indication

• 11 June 2020: OIA response: Official complaints

• 25 May 2020: OIA response: Cost increases caused by COVID-19

• 18 May 2020: OIA response: Funding applications declined

• 23 April 2020: OIA response - Consumer Advisory Committee (CAC)

• 20 April 2020: OIA response: Widely dispensed medicines

• 16 April 2020: OIA response - Fentanyl

• 7 April 2020: OIA response - PTAC’s record of consideration for hypothyroidism Nov 2018

• 3 April 2020: OIA response - Levothyroxine supply

• 31 March 2020: OIA response: Vinorelbine

• 31 March 2020: OIA response: Effect of COVID-19 on medicine supply

• 18 March 2020: OIA response - Supply of funded medicine

• 17 March 2020: OIA Response: Medicines from China

• 17 March 2020: OIA response: Anti-epileptic medicines

• 17 March 2020: OIA response: PrEP Data

• 16 March 2020: OIA response: Preparations for COVID-19

• 13 March 2020: OIA response: Security of supply of medicines

• 12 March 2020: OIA response: Supply of cladribine and dacarbazine

• 9 March 2020: OIA response: New Zealand Pharmaceutical Market

• 28 February 2020: OIA response: Utrogestan SA

• 27 February 2020: OIA response: Anti-rejection medications for transplant patients

• 24 February 2020: OIA response: Lamotrigine brand change

• 24 February 2020: OIA response: Cilazapril with hydrochlorothiazide

• 24 February 2020: OIA response - Ibrutinib

• 20 February 2020: OIA response - PHARMAC's budget

• 11 February 2020: OIA response: Lamotrigine exceptional circumstances applications

• 4 February 2020: OIA response: Hospital purchases of special foods

• 3 February 2020: OIA response: Tafamidis and amyloidosis

• 31 January 2020: OIA response: Mirena statistical information

• 30 January 2020: OIA response: Zapril

• 14 January 2020: OIA response: Asthma inhaler devices dispensed